Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James F Howard

Showing results (21-30 of 131) with videos related to

Pageof 14
Sort By:
Muscle & Nerve|April 24, 2018
Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain studyJohn Vissing, Fanny O'Brien, Jing Jing Wang, et al.
Journal of the Neurological Sciences|June 1, 2025
Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE studyKimiaki Utsugisawa, Masayuki Masuda, Babak Boroojerdi, et al.
Journal of Clinical Neuromuscular Disease|May 24, 2022
Electrodiagnostic Findings in Riboflavin Transporter Deficiency Type 2Jose A Sanchez, Rebecca Traub, Steven P Trau, et al.
Global Epidemiology|May 15, 2024
Evaluating algorithms for identifying incident Guillain-Barré Syndrome in Medicare fee-for-service claimsSamantha R Eiffert, Brad Wright, Joshua Nardin, et al.
Journal of Neurology|March 20, 2020
'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumabJohn Vissing, Saiju Jacob, Kenji P Fujita, et al.
Neuropsychiatric Disease and Treatment|December 7, 2023
Ravulizumab in Myasthenia Gravis: A Review of the Current EvidenceTuan Vu, Heinz Wiendl, Masahisa Katsuno, et al.
Journal of the American Veterinary Medical Association|November 30, 2005
Myokymia and neuromyotonia in a catHeather R Galano, Natasha J Olby, James F Howard, et al.
Annals of Clinical and Translational Neurology|May 27, 2021
Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analysesJames F Howard, Chafic Karam, Marcus Yountz, et al.
Annals of the New York Academy of Sciences|October 25, 2017
Learning from the past: reflections on recently completed myasthenia gravis trialsMichael Benatar, James F Howard, Richard Barohn, et al.
Eclinicalmedicine|December 6, 2024
In response to: "Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee" by Greco et alJames F Howard, Susan M Manzi, Milos D Miljkovic, et al.
Pageof 14

Showing results (21-30 of 131) with videos related to

Sort By:
Pageof 14
Muscle & Nerve|April 24, 2018
Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain studyJohn Vissing, Fanny O'Brien, Jing Jing Wang, et al.
Journal of the Neurological Sciences|June 1, 2025
Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE studyKimiaki Utsugisawa, Masayuki Masuda, Babak Boroojerdi, et al.
Journal of Clinical Neuromuscular Disease|May 24, 2022
Electrodiagnostic Findings in Riboflavin Transporter Deficiency Type 2Jose A Sanchez, Rebecca Traub, Steven P Trau, et al.
Global Epidemiology|May 15, 2024
Evaluating algorithms for identifying incident Guillain-Barré Syndrome in Medicare fee-for-service claimsSamantha R Eiffert, Brad Wright, Joshua Nardin, et al.
Journal of Neurology|March 20, 2020
'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumabJohn Vissing, Saiju Jacob, Kenji P Fujita, et al.
Neuropsychiatric Disease and Treatment|December 7, 2023
Ravulizumab in Myasthenia Gravis: A Review of the Current EvidenceTuan Vu, Heinz Wiendl, Masahisa Katsuno, et al.
Journal of the American Veterinary Medical Association|November 30, 2005
Myokymia and neuromyotonia in a catHeather R Galano, Natasha J Olby, James F Howard, et al.
Annals of Clinical and Translational Neurology|May 27, 2021
Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analysesJames F Howard, Chafic Karam, Marcus Yountz, et al.
Annals of the New York Academy of Sciences|October 25, 2017
Learning from the past: reflections on recently completed myasthenia gravis trialsMichael Benatar, James F Howard, Richard Barohn, et al.
Eclinicalmedicine|December 6, 2024
In response to: "Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee" by Greco et alJames F Howard, Susan M Manzi, Milos D Miljkovic, et al.
Pageof 14